Covid 19
Mutant Covid-19: 2 infected people found in Kashmir
The discovery of two locals carrying the new UK COVID-19 strain is disturbing since there has been a decline in the number of daily COVID positive cases in Kashmir. Dr Bilquees Shah, nodal officer for COVID-19 at Jawaharlal Nehru Memorial (JLNM) hospital in Rainawari area of Srinagar, told reporters that two male patients from Kashmir have tested positive for the new COVID-19 strain that was first reported in the United Kingdom.
COVID-19 Vaccine: Second dry run today ahead of roll-out | 5 Points
This exercise will expose any loophole in the distribution system along with logistical or training problem. The first massive dry run took place on January 2. States like Uttar Pradesh, Haryana and Arunachal Pradesh will not be participating in this dry run as they have already conducted it in all their districts.
Covid-19 Update: India records 18,139 fresh cases, 234 deaths
India continued its streak of low daily new cases. Till now, 1,00,37,398 have recovered. Currently, there are 2,25,449 active cases. The recovery rate stands at 96.36 per cent while the fatality rate is 1.45 as per cent. The total number of samples tested up to January 7 is 17,93,36,364 including 9,35,369 samples tested on Thursday, the Indian Council of Medical Research said.
Harsh Vardhan to meet state health ministers on Covid-19 vaccine's dry-run
The Central government is gearing up for the roll out of Covid-19 vaccine across the country. As a simulation of actual execution, another round of dry run will now be conducted in all 700 plus districts of all states and UTs, except Uttar Pradesh and Haryana, on Friday.
India records 20,346 fresh Covid-19 cases, 222 deaths
India continued its streak of low daily new cases. Till now, 1,00,16,859 have recovered. Currently, there are 2,28,083 active cases. The recovery rate stands at 96.36 per cent while the fatality rate is 1.45 as per cent. The total number of samples tested up to January 6 is 17,84,00,995 including 9,37,590 samples tested on Wednesday, the Indian Council of Medical Research said.
Despite 2 approved vaccines, 69% Indians hesitant to take them
The Drugs Controller General of India (DCGI), on Sunday, announced the approval of two vaccines -- Oxford-AstraZeneca's Covishield manufactured by Serum Institute of India and Bharat Biotech's Covaxin -- against coronavirus infection for restricted emergency use.
Covaxin Controversy: SII, Bharat Biotech bury the hatchet
"Both companies respect the great work being carried out by each other and put behind us the miscommunication and misunderstanding caused during the past week. We are fully aware of the importance of vaccines for people and countries alike, we hereby communicate our joint pledge to provide global access for our Covid-19 vaccines," they said in a joint statement.
COVID-19 vaccination: People under-50 with comorbidities will need doctor’s certificate to register on Co-WIN app
According to the protocol, a scoring system will be set up along with a framework of criteria that doctors can monitor while certifying an individual. However, the certificate does not need fresh check-ups and can be certified by the doctors based on previous test reports and existing medical records of the patient, Times of India reported quoting unnamed sources.
UK Covid-19 Variant: 3 more patients detected with mutant strain in Delhi's LNJP Hospital
Dr Suresh Kumar, Medical Director of Lok Nayak Jai Prakash (LNJP) Hospital informed that the three new cases were detected from a laboratory in Delhi. "The total number of patients suspected of being infected by the UK strain has reached 49. Of them, the strain is confirmed in the seven persons. Three new detections were reported from the Institute of Genomics and Integrative Biology (IGIB) in Delhi," he said.
Covaxin Controversy: Don't accuse us of inexperience, we are a global company, says Bharat Biotech
Bharat Biotech Chairman Krishna Ella said the company conducts clinical trials not only in India but also many other countries. His comments assume significance as Covaxin has been given an emergency approval despite allegedly only two of the required three trial phases being completed.
Advertisement